Vincristine liposomal (Marqibo)
In clinical trials. Also known as Optisome.
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Marqibo involves nanoparticle-encapsulation of vincristine, which is hypothesized to provide improved tissue drug penetration and reduced toxicity.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
- Vincristine patient drug information - note: this is for the non-liposomal formulation (Chemocare)[2]